News Release, KYORIN Pharmaceutical Co.,Ltd.

Kyorin Pharmaceutical and Daiichi Sankyo Brasil Reach Agreement in Brazil for Activities Related to the Development and Marketing of Imidafenacin

Tue, 08 Nov 2011 15:37:34 +0900

Release of "Uritos® OD Tablets 0.1mg" a Drug for Overactive Bladder

Tue, 05 Apr 2011 09:39:15 +0900

Kyorin signed a License Agreement with Almirall on COPD Therapeutic Agent "Aclidinium Bromide" for Japan Territory

Thu, 24 Feb 2011 19:32:02 +0900

KYORIN Group's Participation in Environmental Hygiene

Mon, 21 Feb 2011 19:26:00 +0900

Approval Received for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder

Fri, 12 Nov 2010 09:14:03 +0900

Extension of License Rights Regarding KRP-203

Mon, 08 Nov 2010 14:42:26 +0900

RELEASE OF "MUCODYNE® DS50%"

Tue, 08 Jun 2010 18:53:23 +0900

KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Keiji Hirai), a subsidiary of KYORIN Co., Ltd. announces the release of Mucodyne® DS50% (Nonproprietary name: L-Carbocisteine), a mucoregulating drug (for adults and children) today.

MARKETING APPROVAL FOR "MUCODYNE® DS50%"

Mon, 18 Jan 2010 17:12:02 +0900

KYORIN Pharmaceutical Co., Ltd. (Headquarter: Tokyo, President: Keiji Hirai), a subsidiary of KYORIN Co., Ltd. announced today that the Ministry of Health, Labour and Welfare approved "MUCODYNE® DS50%" (INN: L-Carbocisteine), Mucoregulating drug, on January 15, 2010.

Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder

Thu, 07 Jan 2010 15:59:18 +0900

Kyorin Pharmaceutical Co., Ltd. ("Kyorin") (Tokyo, Japan, President: Keiji Hirai, Ph.D.), a wholly owned subsidiary of Kyorin Co., Ltd., and Ono Pharmaceutical Co., Ltd. ("Ono") (Osaka, Japan, President: Gyo Sagara) jointly announced that each company filed a new drug application for orally disintegrating tablet of imidafenacin (INN), a drug for the treatment of overactive bladder on December 24, 2009. It was originally launched in June 2007 as Uritos Tablets 0.1mg (by Kyorin) or Staybla Tablets 0.1mg (by Ono) in a form of conventional film coating tablets.

Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory

Thu, 05 Nov 2009 09:47:17 +0900

KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Chiyoda-ku, Tokyo, President: Keiji Hirai, Ph.D.), a wholly owned subsidiary of KYORIN Co., Ltd., today entered into a License Agreement for Neramexane, a tinnitus treatment product currently being developed in the US and Europe, with Merz Pharmaceuticals GmbH ("Merz") (Head office: Frankfurt am Main, Germany, CEO: Martin Zügel, Ph.D.) for the territory of Japan.

KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries

Tue, 29 Sep 2009 14:15:40 +0900

Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China

Mon, 27 Jul 2009 15:33:43 +0900

KYORIN Co., Ltd. announces that its wholly owned subsidiary of KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Tokyo, President: Keiji Hirai, Ph.D.) today signed a License Agreement with Senju Pharmaceutical Co., Ltd. ("Senju") (Head office: Osaka, President: Yukoh Yoshida), concerning the grant of an exclusive marketing right to Senju on Gatifloxacin ophthalmic solution for China. Gatifloxacin is a broad spectrum synthetic antibacterial agent originated by Kyorin.

Change of Representative Director and President at KYORIN Pharmaceutical

Fri, 03 Apr 2009 19:28:36 +0900

KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Co., Ltd., announces that a meeting of its Board of Directors held on April 3, 2009 informally resolved to make the change of KYORIN Pharmaceutical's Representative Director and President.
The change will be made pending a resolution of the ordinary general shareholders meeting of KYORIN Pharmaceutical scheduled in June 2009 and a subsequent meeting of the Board of Directors of KYORIN Pharmaceutical.

Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACO

Fri, 27 Feb 2009 15:21:15 +0900

KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd. (Head office: Tokyo, President: Itaru Kojo) has entered into a License and Supply Agreement with Saudi Pharmaceutical Industries & Medical Appliances Corporation ("SPIMACO") (Head office: Riyadh, Saudi Arabia, President: Dr. Abdullah Bin Abdulaziz Al Abdulkader), under which KYORIN Pharmaceutical granted to SPIMACO an exclusive right to develop, register, import, and market Uritos® Tablets (generic name: Imidafenacin), a therapeutic agent for overactive bladder (OAB) in thirteen countries in the Middle East and North Africa (MENA) region, including Saudi Arabia.

Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen for THE LANCET Paper of the Year 2008

Thu, 29 Jan 2009 08:19:40 +0900

Tokyo-January 29, 2009, KYORIN Co., Ltd. announces that a research paper※１on a clinical trial (PEACE Study※２) of MUCODYNE®, sold by its wholly owned subsidiary KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Itaru Kojo), has been selected Paper of the Year by THE LANCET.